This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients. (CIRES)

This study has been completed.
Information provided by (Responsible Party):
Foundation for Liver Research Identifier:
First received: January 15, 2007
Last updated: January 26, 2017
Last verified: January 2017


To evaluate the effects of peginterferon and ribavirin therapy on the immune response in chronic HCV genotype 1,2 or 3 patients before, during and after treatment.


Treatment of chronic hepatitis C (HCV) has shown a remarkable success. However, genotype 1 patients have reduced response rates. A better understanding and improvement of these results can now be considered the greatest challenge.

In chronically infected patients, HCV-specific immune responses are generally weak, narrowly focused, and often dysfunctional. The presence of HCV-specific cells suppressing the immune response (regulatory T-lymphocytes=Treg) are able to suppress the immune response. These Treg are possibly responsible for the impaired immune response.

Previous studies have indicated increased Treg frequency and activity of immune regulating mechanisms, locally in the liver, as a result of HCV re-infection. Hence, these Data highlight the importance of monitoring intrahepatic immune responses in addition to peripheral immune responses. Using the minimally-invasive technique of fine-needle aspiration biopsy (FNAB), it is now possible to obtain safe and frequent liver samples to monitor local antiviral immune responses in chronic HCV patients during antiviral therapy.

Rationale and hypothesis of the study

Our previous studies and current literature support the concept that Treg may contribute to HCV persistence by suppressing HCV-spec immune responses. The current study is designed to examine if peginterferon and ribavirin therapy affects the activity of Treg and DC, and if this results in enhanced HCV-specific immune responses.


Single centre, translational and observational open label study with one arm of 20 genotype 1 patients and one arm of 7 genotype 2/3 patients.

Condition Intervention
Hepatitis C Liver Immunology Regulation Procedure: fine-needle aspiration biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Immune Responses in Chronic Hepatitis C Genotype 1,2,3 Virus Infected Patients During Treatment With Pegylated Interferon-alpha-2b and Ribavirin (CIRES).

Resource links provided by NLM:

Further study details as provided by Foundation for Liver Research:

Biospecimen Retention:   Samples With DNA
PBMC Serum RNA Liver infiltrating lymphocytes

Enrollment: 20
Study Start Date: January 2007
Study Completion Date: November 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Chronic HCV Genotype 1 monoinfection, never had interferon and ribavirin treatment
Procedure: fine-needle aspiration biopsy
aspiration of intrahepatic cells
Chronic HCV Genotype 2 or 3 monoinfection,never had interferon and ribavirin treatment
Procedure: fine-needle aspiration biopsy
aspiration of intrahepatic cells


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients chronically infected with HCV-genotype 1,2 or 3

Inclusion Criteria:

  • Male and female patients between 18-70 years of age, with evidence of a chronic hepatitis C - Genotype 1,2 or 3 infection.
  • No previous treatment with, peginterferon or conventional interferon plus ribavirin combination therapy.
  • Indication for antiviral therapy of hepatitis C according to current clinical guidelines.
  • Written informed consent.

Exclusion Criteria:

  • History or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigators, unsuitable for the study.
  • Presence of contra-indications for antiviral therapy with peginterferon or ribavirin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00422838

Department of Gastroenterology & Hepatology, Erasmus Medical Center
Rotterdam, Zuid-Holland, Netherlands, 3015 GD
Sponsors and Collaborators
Foundation for Liver Research
Principal Investigator: R.J. de Knegt, MD, PhD Department of Gastroenterology & Hepatology - Erasmus Medical Center Rotterdam
Principal Investigator: H.L.A. Janssen, MD, PhD Department of Gastroenterology & Hepatology - Erasmus Medical Center Rotterdam
  More Information

Additional Information:
Responsible Party: Foundation for Liver Research Identifier: NCT00422838     History of Changes
Other Study ID Numbers: CIRES
Study First Received: January 15, 2007
Last Updated: January 26, 2017

Keywords provided by Foundation for Liver Research:
Hepatitis C
Genotype 1,2,3
Pegylated interferon

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017